Single-drug versus combination antimicrobial therapy in critically ill patients with hospital-acquired pneumonia and ventilator-associated pneumonia due to Gram-negative pathogens: a multicenter retrospective cohort study.
François BarbierClaire DupuisNiccolò BuettiCarole SchwebelÉlie AzoulayLaurent ArgaudYves CohenVivien Hong Tuan HaMarc GainnierShidasp SiamiJean-Marie ForelChristophe AdrieÉtienne de MontmollinJean ReignierStéphane RucklyJean-Ralph ZaharJean-François Timsitnull nullPublished in: Critical care (London, England) (2024)
Initial combination therapy exerts no independent impact on Day-28 mortality, clinical cure rate at Day 14, and the hazard of death or AKI at Day 7 in critically ill patients with mono-bacterial HAP, vHAP or VAP due to Gram-negative bacteria.
Keyphrases
- gram negative
- combination therapy
- multidrug resistant
- acute kidney injury
- adverse drug
- staphylococcus aureus
- healthcare
- cardiovascular events
- respiratory failure
- community acquired pneumonia
- cross sectional
- acute care
- stem cells
- clinical trial
- risk factors
- coronary artery disease
- cardiovascular disease
- double blind
- drug induced
- cell therapy
- electronic health record
- mechanical ventilation